Notice Director’s Report Management Discussion Report on Corporate Auditor’s Report
Balance Sheet Profit and Loss Notes Forming Case Flow Proxy Form

COLINZ LABORATORIES LTD.

NOTES  FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 As at   As at 
 March 31, 2012   March 31, 2011 
Notes 1 - Share Capital
a Authorised:
60,00,000 (Previous Year 60,00,000) Equity Shares of Rs.10 each 60,000,000 60,000,000
b Issued, Subscribed and Paid-up:
Issued:
45,76,000 Equity shares of Rs. 10 each.
Subscribed and paid-up:
45,71,000 (Previous Year 45,71,000) Equity Shares of Rs.                         35,435,000                       35,435,000
10 each fully/Partly  paid-up 35,435,000 35,435,000
                                                    
c Par Value per share is Rs. 10  
d Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period;
Particulars No.  Rs.  No.  Rs. 
Shares outstanding at the beginning of the year  3543500 35,435,000 3543500 35,435,000
Shares Issued during the year  0 0 0 0
Shares bought back during the year 0 0 0 0
Any other movement (please specify) 0 0 0 0
Shares outstanding at the end of the year     3543500    35,435,000 3543500 35,435,000
e shares in the company held by each shareholder holding more than 5 percent shares specifying the number of shares held
Name of the shareholder No. of shares  % of holding No. of shares  % of holding
L S Mani 705050 15.4244 705050 15.4244
Vijaya Mani 386000 8.4445 208750 4.5668
f For the period of five years immediately preceding the date as at which the Balance Sheet is prepared: Aggregate No. of Shares (for last 5 Financial Years)
Particulars  
   
Fully paid up pursuant to contract(s) without payment being received in cash Nil
Fully paid up by way of bonus shares Nil
Shares bought back Nil
g Unpaid Calls No. of shares Rs. No. of shares Rs.
By Directors 0 0 0 0
By Officers 0 0 0 0
By Others 2055000 10,275,000 2055000 10,275,000
Notes 2 - Reserves & Surplus
a. Capital Reserves:
State Special Capital Incentive Received Rs. Rs. Rs. Rs.
         Opening Balance 3,100,000   2,700,000  
        (+) Current Year Transfer 400,000   400,000  
        (-)  Written back in the current year 0   0  
        Closing balance   3,500,000   3,100,000
b. Share Premium Account
         Opening Balance 15,220,250   15,220,250  
        (+) Current Year Transfer 0   0  
        (-)  Written back in the current year 0   0  
        Closing balance   15,220,250   15220250
c. Profit & Loss Account
         Opening Balance 6,526,010   5,797,184  
        (+) Current Year Transfer     1,104,250   728,826  
        (-)  Transfer to Other Reserves 0   0  
        Closing balance   7,630,260   6,526,010
Total [a+b+c]   26,350,510   24,846,260

 

(Top)


COLINZ LABORATORIES LTD.

NOTES  FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 As at   Total As at 
 March 31, 2012   March 31, 2011 
Notes 3 - Long Term Borrowings
Secured-From Banks
Cash Credit Account with Bank of Baroda 8,794,822  11,591,998
[Secured by Hypothecation of Stock in Trade/Book debts]
Term loan from Bank of Baroda    -    1,394,146
[Secured by hypothecation of plant and machinery at Sinnar 
 factory]
Car Loan from Axis Bank  712,898      97,502
[Secured against hypothecation of car]
9,507,720 13,083,646
Unsecured Loans -Others
Sales tax deferred (Interest free) 14,410,131  15,382,815
[As per Package Scheme of Incentive of Maharashtra state 
 government and includes VAT and CST]
 14,410,131 15,382,815
   
Total 23,917,851 28,466,461
Notes 4- Trade Payables
Sundry Creditors: 
a) Micro and small enterprises *                         -                           -  
b) Others   9,216,354  6,630,085
* [Determined to the extent such particulars have been identified
on the basis of information available with the Company. This has
been relied upon by the auditors]
  9,216,354    6,630,085
Notes 5- Other Current Liabilities
Statutory liabilities    875,131    743,958
Other Liabilities  2,651,184  1,787,600
Provisions 530,453 505,522
        4,056,768        3,037,080

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE BALANCE SHEET AS AT MARCH 31, 2012

Notes 6 - Fixed Assets

DESCRIPTION GROSS BLOCK DEPRECIATION NET BLOCK
  As at 1.4.2011 Additon in Deduction As at 31.3.2012 As at 1.04.2011 Depreciation  Deduction Up to 31.3.2012 As at 31.3.2012 As at 31.3.2011
    2011-12       for the year        
             
A. Tangible Assets            
LAND 2574350 0 0 2574350 0 0 0 0 2574350 2574350
[Including Land Developing Exps]            
BUILDING- Factory 24027330 0 0 24027330 6696310 802513 0 7498823 16528507 17331020
BUILDING-Office 6580717 0 0 6580717 813898 107266 0 921164 5659553 5766819
PLANT & MACHINERY 11187512 0 0 11187512 5189574 531407 0 5720981 5466531 5997938
LABORATORY EQUIPMENTS 1570542 0 0 1570542 695390 74601 0 769991 800551 875152
FACTORY EQUIPMENTS & TOOLS 3223653 0 0 3223653 1289687 153124 0 1442811 1780842 1933966
ELECTRICAL INSTALLATION 2377531 0 0 2377531 1152252 112722 0 1264974 1112557 1225279
CENTRAL A.C. PLANT 8176691 0 0 8176691 2198075 388393 0 2586468 5590223 5978616
OFFICE EQUIPMENTS 592660 0 0 592660 380715 28151 0 408866 183794 211945
COMPUTER 644888 0 0 644888 578776 14220 0 592996 51892 66112
FURNITURE & FIXTURE 3469439 0 0 3469439 2054191 219616 0 2273807 1195633 1415248
VEHICLES 1544416 996363 605322 1935457 789970 167454 438305 519119 1416338 754446
Total Tangible Assets 65969729 996363 605322 66360770 21838838 2599467 438305 24000000 42360771 44130891
                     
B. Intangible Assets 0 0 0 0 0 0 0 0 0 0
                     
TOTAL ASSETS 65969729 996363 605322 66360770 21838838 2599467 438305 24000000 42360771 44130891
PREVIOUS YEAR 65913844 55885 0 65969729 19261313 2577525 0 21838838 44130891 46652531

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 As at   Total As at 
Face Value No. of shares  March 31, 2012   March 31, 2011 
Notes 7- Non-Current Investments
(a)   Equity shares [fully paid, quoted]
3i Infotech 10 600 30000 30000
Hubtown Ltd. 10 12 6480 6480
Ansal Properties & Infrastructure Ltd. 5 200 101,926 101,926
Arvind Mills 10 500 60681 60681
Bajaj Holdings & Investments Ltd. 10 50 73319 73319
Bajaj Auto  Ltd. 10 100 28678 28678
Bajaj Finserv Ltd. 5 50 27770 27770
Bank of Baroda 10 500 118534 118534
Bank of Maharashtra 10 300 6900 6900
Bell Ceramics 10 333 21880 21880
Bharat Forge Ltd. 2 30 3804 3804
Bharti Shipyard Ltd. 10 200 64841 64841
Cairn India Ltd 10 1015 162400 162400
CESC Ltd  10 200 128627 128627
Coal India Ltd 10 88 21560 21560
Eveready Industries Ltd. 5 500 17645 17645
GTL Infrastructure Ltd 10 213 4000 4000
Gujarat Sidhee Cement Ltd 10 1000 24186 24186
HFCL Ltd. 1 500 12192 12192
HDFC  Ltd. 2 100 64762 64762
HDIL 10 100 14505 14505
Hindustan Organic Chemicals Ltd 10 1000 66283 66283
Hindustan Oil Exploration Co Ltd 10 500 81322 81322
IDBI Ltd 10 200 15717 15717
IDFC Ltd 10 2000 164446 164446
Idea Cellular Ltd 10 990 130834 130834
IRB Infrastructure  ltd 10 100 16457 16457
Jagran Prakashan Ltd 2 143 27967 27967
Kausalya Infrastructure Ltd 10 176 10560 10560
Kingfisher Airlines 10 200 10641 10641
Lanco Infrastructure Ltd 1 3210 77040 77040
Macleod Russels Ltd 5 250 8823 8823
Mahindra Lifespace Developers 10 200 184668 184668
Maars Software Ltd 10 5000 57340 57340
Morepen Laboratories Ltd. 2 500 7455 7455
NTPC Ltd 10 500 71801 71801
Neyveli Lignite Ltd. 10 400 22868 22868
Panama Petrochem Ltd 10 250 32369 32369
Polaris Software Lab Ltd. 5 200 32299 32299
Punj Lloyd Ltd 2 500 99416 99416
Pyramid Saimira Theatre Ltd 10 60 6000 6000
Ranbaxy Labs. Ltd. 5 100 46004 46004
Reliance Capital Ltd 10 10 1130 1130
Reliance Communication Ltd 5 200 33654 33654
Reliance  Infrastructure 10 15 6348 6348
Reliance Power Ltd 10 74 7358 7358
Simplex Infrastructure Ltd 2 200 76982 76982
SeaMac 10 1000 192315 192315
Sesa Goa 1 100 28407 28407
Sonata Software Ltd 1 1000 52218 52218
Spicejet Ltd 10 250 15138 15138
Tamilnadu Petroproducts Ltd. 10 500 17290 17290
Tanla Solutions Ltd 1 50 6625 6625
Tata Tele (Mah) Services Ltd. 10 700 20634 20634
Unitech Ltd 2 200 44887 44887
United phosphorus 2 100 14083 14083
Voltamp Transformers Ltd 10 100 63163 63163
Wipro Ltd 2 83 13537 13537
Total (a)           2,758,769            2,758,769
[The market value of the quoted shares is Rs. 27,33,667/- ]
(a)   Mutual Funds & Others (Un-Quoted)
UTI Master Value Fund 33.89 8852.169             300,000                 300,000
JM Infra & Agricultural Fund 10 10000                 100,000                 100,000
Total (b)               400,000                400,000
Total Investments [a+b]  3,158,769            3,158,769

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 As at   Total As at 
 March 31, 2012   March 31, 2011 
Notes 8 - Long Term Loans & Advances
Security Deposits               713,150                709,150
Loans to Companies          13,050,000           13,250,000
         13,763,150           13,959,150
Notes 9- Other Non-Current Assets
Cash and Cash Equivalants
Fixed Deposits maturing after 12 months               524,850                          -  
              524,850                         -  
Notes 10 - Inventories 
Raw Materials [Valued at the lower of cost (first in first out) and estimated net realisable value]            2,468,041             1,604,693
Packing Materials [Valued at the lower of cost (first in first out) and estimated net realisable value]            1,339,510                992,729
Work-in-Progress [Valued at the lower of cost and estimated net realisable value]                 59,875                168,054
Finished Goods [Valued at the lower of cost and estimated net realisable value]          17,465,638           16,262,247
         21,333,064           19,027,723
Notes 11 - Trade Receivables
(Unsecured and considered good)
Debts Outstanding For a Period Exceeding Six Months 1,243,083                    1,340,585 
Other Debts      9,599,737        7,891,702 
     
         10,842,820             9,232,287
Trade Receivable stated above include debts due by:
Directors *                         -                           -  
Other officers of the Company *                         -                           -  
Firm in which director is a partner *                         -                           -  
Private Company in which director is a member                         -                           -  
*Either severally or jointly 
Notes 12 - Cash and Cash Equivalents
Cash in Hand               358,547                390,818
Balances with Banks on:
 -  Current Accounts            5,135,607             8,823,134
 -  Fixed Deposit Accounts             3,764,059             2,500,000
 Less: Restricted Cash                         -                            -  
           9,258,213           11,713,952
Notes 13 - Short Term Loans and Advances
(Unsecured and considered good, unless otherwise stated)
a Loans and advances to related parties                          -                           -  
b Others
Balances With Central Excise Authorities                 53,999                  47,897
Advance to Employees               236,778                208,943
Advance to Suppliers/Service Providers - -
Pre-paid Expenses 141,001 178,970
VAT Refund Receivable 304,075 180,338
Tax Deducted at Source and Advance Tax 197,257 134,846
  933,110 750,994

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 Year ended   Year ended 
 March 31, 2012   March 31, 2011 
Notes 14 - Operating Revenue
Sale of Products             70,454,561             60,336,549
70,454,561 60,336,549
Notes 15 - Other Income
Interest on:
( - Bank Deposits [including tax deducted at source Rs.31,867 )                 320,777                   93,512
   (Previous year Rs. 15,281)]
 - Dividend                   47,777                   62,791
Profit on Sale of shares                          -                     65,679
368,554                221,982
Notes 16- Cost of Materials Consumed
Opening Stock               2,597,421               3,047,824
Add: Purchases              25,627,544             20,583,267
      28,224,965       23,631,091
Less: Closing Stock             (3,807,551)             (2,597,421)
          24,417,414           21,033,670
Notes 17 -Changes in inventories of finished goods work-in-progress and Stock-in-Trade
Opening Stock:
 - Finished Goods             16,262,247             13,368,881
 - Work-in-Progress                 168,054                 750,470
         16,430,301         14,119,351
Less: Closing Stock:
 - Finished Goods             17,465,638             16,262,247
 - Work-in-Progress                   59,875                 168,054
    17,525,513        16,430,301
      (1,095,212)           (2,310,950)
Notes 18 - Employee Benefit Expense
Salaries and Allowances             21,762,964             18,387,433
Contribution to Provident and Other Funds                 593,242                 619,457
Gratuity                  187,400                   40,800
          22,543,606           19,047,690

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 Year ended   Year ended 
 March 31, 2012   March 31, 2011 
Notes 19 - Finance Cost
Interest Expences: 1,892,853 1,560,718
                             
         1,892,853            1,560,718
Notes 20 - Other Expense
Block & Designs                 30,675                 20,250
Consumables               173,618               235,256
Laboratory Expenses                 92,405               108,400
AC Rental Charges               175,848               132,778
Office Rent               180,000               180,000
Analytical Charges               288,708               223,745
Office Expenses               572,832               587,384
Conveyance               373,022               341,184
Motor Car Expenses               171,898               181,939
Factory Security Expenses 274,759               141,944
Repairs and Maintenance:
- Plant and Machinery                 36,022                 76,416
- Building               269,474                         -  
- Others               195,600               102,833
Freight & Forwarding            1,390,682            1,396,225
Insurance               116,670                 90,071
Loan License Charges Paid            1,312,568            1,349,788
Auditors’ Remuneration                  90,446                 85,096
Power & Fuel               710,954               690,907
Printing & Stationery               105,900                 65,758
Books & Periodicals                 30,000                 19,100
Postage & Telegram               345,243               263,182
Legal & Professional Fees               413,242               599,037
Loss on sale of assets               120,017                         -  
Taxes & License Fees               318,568               367,538
Society Maint. Charges                 71,402                 79,339
Telephone Charges               439,975               263,352
Travelling Expenses               614,895            1,218,260
Commission on sales               927,386               912,993
Directors' Remuneration            1,711,000            1,549,000
Advertisement (Recruitment & Statutory)               119,903               204,648
Water Charges     19,964                 20,365
11,693,676   11,506,788

 

(Top)


 

SCHEDULE 21: SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO THE FINANCIAL STATEMENTS :-

a) Significant Accounting Policies:

i]   General :
The Financial statements are prepared under historical cost convention on an accrual basis and comply with the accounting standards referred to in Section 211 ( 3C ) of the Companies Act, 1956.

ii]  Fixed Assets:
Fixed assets are stated at original cost net of tax / duty credits availed, if any.

iii] Capital work in progress:
The capital work in progress as on 31-03-2012 is Rs. Nil

iv]  Depreciation :
Fixed Assets are depreciated under Straight Line Method. The applicable rates are as provided under Schedule XIV to the Companies Act, 1956. Depreciation on additions / deletions of  assets during the year is provided on a pro-rata basis.

v]  Inventories:
Raw materials and packing materials are valued at cost on FIFO basis as per revised Accounting Standard AS-2 of the Institute of Chartered Accountants of India. Finished goods and semi-finished goods are valued at lower of cost or net realizable value.

vi] Investments:
Investments are stated at cost.

vii] Sales:
Sales are recognized at the time of dispatch of goods. All sales are shown inclusive of excise duty and exclusive of Sales Tax (VAT).

viii] Other income:
Includes  interest on Fixed Deposits with Bank, dividends received and capital gains on the shares sold.

ix]  Research and Development Expenses:
No capitalization of Research and Development expenses is made since no capital expenditure on research and development expenditure has been incurred during the year.

x]  Foreign Currency Transactions:
Export earnings of Rs.Nil (Previous Year - Rs.NIL)
Foreign Exchange Outgo of Rs.NIL (Previous Year – Rs. NIL /-)

xi] Retirement Benefits:
Retirement benefit in respect of gratuity is not provided for, and liability is not         
ascertained.
Privilege leave entitlement: Privilege leave entitlements are recognized as a liability as and when the same is encashed by the employees.
Provident Fund: Contribution to Government provident Fund are made as per the provisions regularly.

b) The figures of previous year have been regrouped wherever necessary.

c) As per the available records, there is no outstanding dues to enterprises registered under Micro, Small and Medium Enterprises Development Act, 2006, at the end of the year. Further, no interest has been paid or payable on delayed payment of dues, if any, to such enterprises during the year

d) Estimated amount of contracts remaining to be executed on capital account and not provided for: Rs.Nil     [ Previous Year : Rs. Nil  ]

e) Contingent Liabilities:
Bills Discounted and Purchased  -  Rs. Nil (Previous Year Rs. Nil )
Others                                         -  Rs. Nil (Previous Year Rs. Nil )

f) Auditors Remuneration :                                                             

  2011-2012  2010-2011
Audit Fees

Rs.   66,180

Rs.   55,150

Tax Audit Fees

Rs.   11,030

Rs.   11,030

Other services

Rs.   13,236

Rs.   18,916

Total

Rs.   90,446

Rs.   85,096

 

g) Segment Reporting

The Company is engaged in pharmaceutical formulation business which as per Accounting Standard – AS 17 is considered the only reportable business segment.

h) Related party transaction

As required by Accounting Standard – AS 18 ‘Related Parties Disclosure’ issued by the Institute of Chartered Accountants of India are as follows :

   (a) Key Management personnel              (b)  Details of Transactions.
(i)  Dr. L. S. Mani.                                          Remuneration paid Rs.8,40,500/-
Rent paid for the premise hired Rs. 1,80,000/-

i) Earning per share

As per Accounting Standard – AS 20 on ‘Earning per Share’ issued by the Institute of Chartered Accountants of India, the earning per share of the Company is Rs. 0.24.

j) Accounting for Taxes on Income.

In accordance with the AS-22, Accounting for Taxes on Income, issued by the Institute of Chartered Accountants of India, deferred tax resulting from timing differences between book and tax profits is accounted for, at the current rate of tax, to the extent the timing differences are expected to crystallize. The deferred tax asset arising on account of brought forward unabsorbed depreciation is recognized only to the extent there is a reasonable certainty of realization.

k) AS – 28 Impairment of Assets.
As on the Balance Sheet date the carrying amounts of the assets net of accumulated depreciation is not less than the recoverable amount of those assets. Hence there is no impairment loss on the assets of the company.

In the opinion of Board of Directors, the Current Assets, Loans and advances have a value which on the realization in the ordinary course of business would at least be equal amount stated in the Balance sheet.

l) With regard to loan given to Company, the Board of Directors are of the opinion that no  interest should be provided in the accounts as the principle amount has not been recovered, Further, no provision for doubtful debt is required to be made as the amount is expected to be recovered in due course.

m) Deferred Tax :
The break up of the deferred tax liability as at 31st March, 2012 is as under:

 

2011-12
Rupees

2010-11
Rupees

Deferred Tax Liability :

 

 

Difference between book depreciation and
depreciation as per Income Tax Act, 1961.

63,62,909

64,30,675

 

63,62,909

64,30,675

Deferred Tax Assets:

32,62,792

29,46,695

Net Deferred Tax  Liability

31,00,117

34,83,980

     

n) The Share Capital includes 4,00,000 Equity Shares of Rs. 10/- each, allotted as fully paid   Bonus Shares  by capitalisation of Capital Reserves in 1994-95.

o) Additional information pursuant to the provisions of paragraph 3, 4C and 4D of Part II of   Schedule VI  to the Companies Act, 1956, as certified by the Directors.Quantitative and Turnover information  for the year ending 31st March, 2012.(Previous year figures are regrouped wherever necessary

i] Manufacturing  Activities :                                                                                                 [Rupees in Lacs]

     
Opening Stock
Closing Stock
Turnover

Class

Units

Actual
production

Qty.

Value

Qty.

Value

Qty.

Value

Tablets

Nos.

121.859

37.990

50.27

41.890

54.09

117.959

188.74

 

in Lacs

137.800)

(26.500)

(52.41)

  (37.990)

(50.27)

(126.31)

(179.10)

 

Capsules

Nos.

83.684

22.790

60.56

15.594

54.08

90.88

324.44

 

in Lacs

(99.870)

(12.030)

(35.74)

(22.790)

(60.56)

(89.11)

(252.59)

 

Liquids

Ltrs.

21090.180

 5605.770

16.88

7697.560

27.34

18998.39

68.53

 

 

(19051.160)

(5384.400)

  (12.12)

(5605.770)

(16.88)

(18829.79)

(58.53)

 

Ointments

Kgs 

3051.73

1256.330

17.88

1385.855

21.58

2922.205

      45.59

 

 

(3739.535)

(816.025)

  (14.68)

(1256.330)

  (17.88)

  (3299.23)

      (49.59)

 

Notes :

  • Installed capacity is based on one shift working as certified by the management and  accepted by the  Auditors without verification being a technical matter.

  • Actual production includes production under Loan License arrangements.

  • Figures in brackets are of previous year.

ii] Particulars of Goods Traded:                                                                                              [Rupees in Lacs]

Class Units Opening Stock Purchases Sales Closing Stock

 

 

Qty.

Value

Qty.

Value

Qty.

Value

Qty.

Value

Liquids

 Ltrs.

483.200

1.24

7253.000

13.28

5591.400

18.69

2144.800

6.67

 

in Lacs

(979.200)

(2.53)

(4124.200)

 (7.67)

(4620.200)

(14.32)

(483.200)

(1.24)

 

Injectables

Nos.

70.646

7.45

-

-

70.646

8.84

-

-

 

in Lacs

(13.860)

(2.87)

(134.606)

(6.74)

(77.820)

(10.98)

(70.646)

(7.45)

 

Capsules

Nos.

1.750

 5.69

9.167

17.49

9.732

37.69

1.185

3.84

 

in Lacs

(0.530)

(1.73)

 (8.580)

(16.04)

(7.360)

(30.60)

(1.750)

(5.69)

 

Tablets

Nos.

1.000

2.65

4.804

3.80

3.434

12.02

     2.370

7.05

 

in Lacs

(3.880)

(11.61)

 -

-

  (2.880)

(7.65)

    (1.000)

(2.65)

 

iii] The quantity and value of consumption of raw materials

Raw Materials (Bulk Drugs) Quantity (Kgs.) Value (Rupees in Lacs)
    2011-12 2010-11 2011-12 2010-11

1

Calcium Pantothenate

456

462

3.39

3.04

2

Vitamin E

330

368

5.90

8.81

3

Meclizine

250

180

20.34

13.58

4

Paracetamol

2150

2450

4.98

6.61

5

Chlorazoxazone

425

300

3.68

1.64

6

Isox suprine Hcl

17

17

2.67

2.15

7

Riboflavin  ( B2)

92

75

2.39

3.74

8

Niacinamide

382

430

2.44

3.45

9

Thiaminemono (B1)

74

80

1.18

1.67

10

Spirulina

4156

2829

22.29

13.77

11

Clindamycin Phosphate

25

5

2.43

1.09

12

Progesterone

150

125

23.92

18.10

13

Menthol

175

170

2.75

1.97

14

Propylene Glycol

1635

1590

2.13

2.54

15

Sorbitol

2227

600

1.16

0.24

16

Fish Oil

360

160

3.63

1.42

17

Folic Acid

90

-

2.82

-

18

Sugar

12550

7500

3.85

2.17

19

P V P K

150

-

1.22

-

20

Ofloxacin usp

120

95

3.20

1.88

21

Quinine Sulphate

25

30

1.71

2.03

22

Mat SR Base III

84

106

1.49

1.76

23

Ornidazole

300

237

3.26

2.26

24

Empty Gelatin Capsule

 

 

10.75

10.39

25

Others

 

 

23.09

18.62

 

                                    Total :

 

 

156.67

 122.93

 


As per our report of even date attached.    
FOR  S. V. BHAT & CO. FOR AND ON BEHALF OF THE BOARD.
Chartered Accountants.    
S. V. BHAT Dr.  L. S. Mani Chairman & Managing Director
Proprietor.  N. K. MENON Director
M. No. 37237 . FIRM REG.NO.101298W  
Mumbai    
Date:15th May, 2012.    

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in